Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Aug 07, 2019

SELL
$31.0 - $36.3 $69,223 - $81,057
-2,233 Closed
0 $0
Q1 2019

May 13, 2019

SELL
$31.58 - $46.35 $86,339 - $126,720
-2,734 Reduced 55.04%
2,233 $75,000
Q4 2018

May 22, 2019

BUY
$30.43 - $56.65 $151,145 - $281,380
4,967 New
4,967 $163,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $174M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Symmetry Partners, LLC Portfolio

Follow Symmetry Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Symmetry Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Symmetry Partners, LLC with notifications on news.